Jane Street
OCUL icon

Jane Street’s Ocular Therapeutix OCUL Stock Holding History

Jane Street’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Sell
35,700
-83,800
-70% -$760K ﹤0.01% 8858
2026
Q1 		$1.01M Buy
119,500
+106,200
+798% +$1.01M ﹤0.01% 6474
2025
Q4 		$161K Buy
13,300
+2,200
+20% +$26.7K ﹤0.01% 9881
2025
Q3 		$130K Sell
11,100
-18,300
-62% -$219K ﹤0.01% 9981
2025
Q2 		$273K Buy
29,400
+2,400
+9% +$18.8K ﹤0.01% 8023
2025
Q1 		$198K Buy
27,000
+3,700
+16% +$28.4K ﹤0.01% 8462
2024
Q4 		$199K Buy
+23,300
New +$227K ﹤0.01% 8416
2024
Q2 		– Sell
-191,900
Closed -$1.75M – 9956
2024
Q1 		$1.75M Buy
191,900
+172,600
+894% +$1.22M ﹤0.01% 4377
2023
Q4 		$86.1K Buy
+19,300
New +$57.1K ﹤0.01% 8636
2022
Q1 		– Sell
-27,100
Closed -$189K – 10820
2021
Q4 		$189K Sell
27,100
-19,300
-42% -$150K ﹤0.01% 8854
2021
Q3 		$464K Sell
46,400
-25,500
-35% -$286K ﹤0.01% 7421
2021
Q2 		$1.02M Buy
+71,900
New +$1.09M ﹤0.01% 5796

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's OCUL Position: Q2 2026 in Review

Jane Street sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 804,589 shares — an estimated $7.29M sold.

Jane Street first reported a position in OCUL in Q2 2018 and held it in 23 quarters. The position peaked at $12.6M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Jane Street reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 804,589 Ocular Therapeutix shares in Q2 2026, an estimated $7.29M.
  • Jane Street first reported a position in Ocular Therapeutix in Q2 2018 and held it in 23 quarters.
  • Jane Street's Ocular Therapeutix position peaked at $12.6M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.